Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.

Item

http://www.wikidata.org/entity/Q45365263

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Pharmacokinetics and safety of ...... in a randomized phase I trial.

@en

Pharmacokinetics and safety of ...... in a randomized phase I trial.

@nl

type

Item

label

Pharmacokinetics and safety of ...... in a randomized phase I trial.

@en

Pharmacokinetics and safety of ...... in a randomized phase I trial.

@nl

prefLabel

Pharmacokinetics and safety of ...... in a randomized phase I trial.

@en

Pharmacokinetics and safety of ...... in a randomized phase I trial.

@nl

P1476

Pharmacokinetics and safety of ...... in a randomized phase I trial.

@en

P2093

Esther Bouman-Thio

http://www.w3.org/2001/XMLSchema#string

Honghui Zhou

http://www.w3.org/2001/XMLSchema#string

Hugh M Davis

http://www.w3.org/2001/XMLSchema#string

Joyce A Ford

http://www.w3.org/2001/XMLSchema#string

Kevin J Petty

http://www.w3.org/2001/XMLSchema#string

Monica Keen

http://www.w3.org/2001/XMLSchema#string

Sally Lyn

http://www.w3.org/2001/XMLSchema#string

Tara Masterson

http://www.w3.org/2001/XMLSchema#string

Yanli Zhuang

http://www.w3.org/2001/XMLSchema#string

Yuan Lv

http://www.w3.org/2001/XMLSchema#string

P2860

Elimination mechanisms of therapeutic monoclonal antibodies

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.

Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.

Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects.

Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

P304

795-800

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40261-013-0124-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23975656

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial